- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06716073
Resultados a largo plazo de la cirugía conservadora de mama asistida por endoscopia frente a la convencional en pacientes con cáncer de mama después de la terapia neoadyuvante: un ensayo aleatorizado, multicéntrico, abierto y de no inferioridad
With the title of "Long-Term Outcomes of endoscopic-assisted vs conventional breast-conserving surgery in breast cancer patients after neoadjuvant therapy: a randomized, multicenter, open label, non-inferiority trial", this study targets breast cancer patients after neoadjuvant therapy. A total of 804 eligible patients, after screening with inclusion and exclusion criteria, will be randomly assigned to Endoscopic-assisted breast conserving surgery(E-BCS) or conventional breast conserving surgery (C-BCS) group at a 1:1 ratio using stratified block randomization method, stratified by centers and molecular subtype. The co-primary endpoints are 5-year disease-free survival (5y-DFS) and Breast-Q score at 6 months after surgery. The secondary endpoints are cosmetic outcomes including surgeons' satisfaction with breast and patients' satisfaction with scar, survival outcomes including 5-year overall survival (5y-OS) and 5-year local-recurrence rate (5y-LRR), surgical outcomes including operative time, intraoperative blood loss, incision length and postoperative complications rate. This study aims to confirm the long-term safety and aesthetic outcome of endoscopic-assisted surgery in breast cancer patients after neoadjuvant treatment by comparing it with conventional open breast conserving surgery, and provide clinical evidence for the popularized application of endoscopic breast surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Shicheng Su
- Número de teléfono: +86-13631304227
- Correo electrónico: sushch@mail.sysu.edu.cn
Copia de seguridad de contactos de estudio
- Nombre: Yiwen Lu, Doctor
- Número de teléfono: +86-13268121885
- Correo electrónico: luyw8@mail.sysu.edu.cn
Ubicaciones de estudio
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510120
- Reclutamiento
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Contacto:
- Shicheng Su
- Número de teléfono: +86-13631304227
- Correo electrónico: sushch@mail.sysu.edu.cn
-
Shantou, Guangdong, Porcelana
- Aún no reclutando
- Sun Yat-sen Memorial Hospital of Sun Yat-sen University Shenzhen Shantou Central Hospital
-
Contacto:
- Yandan Yao
- Número de teléfono: +86-13826292688
- Correo electrónico: yaoyand@mail.sysu.edu.cn
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ranging from 18 to 75 years
- Pathologically confirmed invasive breast cancer
- Receiving preoperative chemotherapy (Each molecular subtype corresponds to unanimous regimen)
- cT1-3N0-3M0
- Unilateral breast tumor
- Eastern Cooperative Oncology Group score 0-1
- Left Ventricular Ejection Fraction (LVEF) ≥50%
- Leukocytes ≥ 3.0×109/L, Absolute neutrophil count ≥ 1.5×109/L, Platelets ≥ 100×109/L, Hemoglobin ≥ 90g/L, Creatinine <1.5 × institutional ULN, Total bilirubin ≤ 2.0 × institutional ULN.
Exclusion Criteria:
- Diffusely disseminated malignant calcification foci
- Not applicable for BCS after neoadjuvant therapy
- Pregnancy or breastfeeding
- Additional malignancy
- Severe cardiopulmonary, liver or kidney dysfunction or other systemic diseases (such as uncontrolled chronic heart failure, critical hypertension or diabetes with poor blood glucose control).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Grupo de cirugía endoscópica de conservación de la mama (E-BCS)
|
comparison of 2 surgical procedures |
|
Sin intervención: Grupo de cirugía conservadora de mama convencional (C-BCS)
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
5-year disease free survival
Periodo de tiempo: From surgery to the end of follow-up at 5 years
|
The proportion of patients remaining after excluding patients with disease recurrence, metastasis or death from the time of surgery to 5-year follow-up |
From surgery to the end of follow-up at 5 years
|
|
Patients' satisfaction with breast
Periodo de tiempo: From surgery to the follow-up at 6 months
|
The score of Breast-Q scale "Satisfaction with breasts" table 6 months after surgery |
From surgery to the follow-up at 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Surgeons' satisfaction with breast
Periodo de tiempo: From surgery to the follow-up at 6 months
|
Surgeons evaluate the cosmetic outcome of breast based on the photos before surgery and after surgery. Four ranks: Excellent (9-10 points), Good (7-8 points), Fair (5-6 points) and Poor (0-4 points) are categorized on a basis of average total score from Ueda scale |
From surgery to the follow-up at 6 months
|
|
Patients satisfaction with scar
Periodo de tiempo: From surgery to the follow-up at 6 months
|
Scar-Q scale including 3 tables about the surgical scar: appearance, symptom, psychosocial impact with total score of 100 will be used for evaluating patients satisfaction with scar |
From surgery to the follow-up at 6 months
|
|
5-year overall survival
Periodo de tiempo: From surgery to the end of follow-up at 5 years
|
The proportion of patients remaining after excluding patients who died from any cause at 5-year follow-up |
From surgery to the end of follow-up at 5 years
|
|
5-year local-regional recurrence rate
Periodo de tiempo: From surgery to the end of follow-up at 5 years
|
The proportion of patients with a lump found on breast, axilla, chest wall, skin or scars of surgery ipsilateral to the surgical side through physical examination or imaging, confirmed as the same pathological type as the primary tumor according to biopsy at 5-year follow up |
From surgery to the end of follow-up at 5 years
|
|
Postoperative complication rate
Periodo de tiempo: From surgery to the follow-up at 12 months
|
The proportion of patients with postoperative complications including hemorrhage, incision dehiscence, upper limb lymphedema, infection,seroma. |
From surgery to the follow-up at 12 months
|
|
Surgical duration
Periodo de tiempo: Intraoperative
|
The time from the beginning of surgery to the end of surgery |
Intraoperative
|
|
Intraoperative blood loss
Periodo de tiempo: Intraoperative
|
The blood loss during the operation |
Intraoperative
|
|
Incision length
Periodo de tiempo: Intraoperative
|
The length of surgical incision |
Intraoperative
|
Colaboradores e Investigadores
Investigadores
- Silla de estudio: Shicheng Su, Doctor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SYSKY-2024-648-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .